NCT04714190 is a Phase 3 clinical trial of RC48-ADC in Gastric Cancer, sponsored by RemeGen Co., Ltd..

Who is sponsoring NCT04714190?

NCT04714190 is sponsored by RemeGen Co., Ltd..

What drugs are being tested in NCT04714190?

Interventions in NCT04714190: RC48-ADC, Paclitaxel injection, Irinotecan Hydrochloride Injection, Apatinib Mesylate Tablets.

What condition does NCT04714190 study?

NCT04714190 studies Gastric Cancer, HER2 Overexpressing Gastric Carcinoma.

Is NCT04714190 still recruiting?

NCT04714190 is currently status unknown. Last updated 21 December 2023.

Last reviewed 2023-12-21 · How we verify

NCT04714190

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression

Status unknown Phase 3 Last updated 21 December 2023

What this trial tests

Phase 3 trial testing RC48-ADC in Gastric Cancer in 351 participants. Status unknown.

Timeline

24 March 2021

Primary endpoint
1 December 2024

30 June 2025

Quick facts

Lead sponsor	RemeGen Co., Ltd.
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	351
Start date	24 March 2021
Primary completion	1 December 2024
Estimated completion	30 June 2025
Sites	52 locations across China

Drugs / interventions tested

RC48-ADC — full drug profile →
Paclitaxel injection — full drug profile →
Irinotecan Hydrochloride Injection
Apatinib Mesylate Tablets — full drug profile →

Conditions studied

Gastric Cancer — all drugs for Gastric Cancer →
HER2 Overexpressing Gastric Carcinoma — all drugs for HER2 Overexpressing Gastric Carcinoma →

Sponsor

RemeGen Co., Ltd. — full company profile →

Who can join

18 and older, any sex, with Gastric Cancer or HER2 Overexpressing Gastric Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase III, randomized, multicenter, open-label clinical trial designed to compare RC48-ADC to physician choice standard treatment in participants with human epidermal growth factor receptor 2 (HER2)-overexpression locally advanced or metastatic gastric cancer.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Gastric cancer treatment: recent progress and future perspectives.
Guan WL, He Y, Xu RH. · · 2023 · cited 639× · PMID 37245017 · DOI 10.1186/s13045-023-01451-3
Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
Ferraro E, Drago JZ, Modi S. · · 2021 · cited 164× · PMID 34380530 · DOI 10.1186/s13058-021-01459-y
Targeting cancer with antibody-drug conjugates: Promises and challenges.
Dean AQ, Luo S, Twomey JD, Zhang B. · · 2021 · cited 145× · PMID 34291723 · DOI 10.1080/19420862.2021.1951427
Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study.
Peng Z, Liu T, Wei J, Wang A, et al · · 2021 · cited 142× · PMID 34665942 · DOI 10.1002/cac2.12214
HER2-targeted therapies in cancer: a systematic review.
Zhu K, Yang X, Tai H, Zhong X, et al · · 2024 · cited 83× · PMID 38308374 · DOI 10.1186/s40364-024-00565-1
Antibody-Drug Conjugates for the Treatment of HER2-Positive Breast Cancer.
Najjar MK, Manore SG, Regua AT, Lo HW. · · 2022 · cited 65× · PMID 36360302 · DOI 10.3390/genes13112065
Novel ADCs and Strategies to Overcome Resistance to Anti-HER2 ADCs.
Díaz-Rodríguez E, Gandullo-Sánchez L, Ocaña A, Pandiella A. · · 2021 · cited 65× · PMID 35008318 · DOI 10.3390/cancers14010154
Molecular Pathways and Mechanisms of HER2 in Cancer Therapy.
Raghav KPS, Moasser MM. · · 2023 · cited 38× · PMID 36574481 · DOI 10.1158/1078-0432.ccr-22-0283

Verify or expand the search:

Other trials of RC48-ADC

Trials testing the same drug.

NCT06074484 — A Study of RC48-ADC Combined With AK104 For Perioperative Treatment of Muscle-Invasive Bladder Cancer · Phase 2 · unknown
NCT06178601 — A Study of RC48-ADC Combined With Cadonilimab（AK104）in the Treatment of HER2-expression Locally Advanced or Metastatic U · Phase 2 · unknown
NCT05514158 — To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 · Phase 1 · unknown
NCT05302284 — A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma · Phase 3 · recruiting
NCT05297552 — A Study of RC48-ADC Combined With JS001 For Perioperative Treatment of Muscle-Invasive Bladder Cancer · Phase 2 · unknown

Other recruiting trials for Gastric Cancer

Currently open trials in the same condition.

NCT07525765 — AI-assisted Decision-making of Reoperation for Postoperative Bleeding of Gastric Cancer · recruiting
NCT07464470 — Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers · recruiting
NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
NCT07431281 — Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Meta · Phase 3 · recruiting
NCT07448493 — Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer · active not recruiting

Other RemeGen Co., Ltd. trials

Trials by the same sponsor.

NCT07537881 — A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC288 in the Treatment of Solid Tumors · Phase 1, PHASE2 · not yet recruiting
NCT07462143 — A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer · Phase 2, PHASE3 · not yet recruiting
NCT07495033 — Phase III Clinical Trial of Telitacicept Injection in the Treatment of Patients With Connective Tissue Disease-related I · Phase 3 · not yet recruiting
NCT07416474 — RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Smal · Phase 3 · not yet recruiting
NCT07249632 — A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG) · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04714190 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by RemeGen Co., Ltd.
Last refreshed: 21 December 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04714190.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing